These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Stimulant and Designer Drug Use: Primary Care Management. Klega AE; Keehbauch JT Am Fam Physician; 2018 Jul; 98(2):85-92. PubMed ID: 30215997 [TBL] [Abstract][Full Text] [Related]
4. Cocaine-induced ANCA-associated renal disease: a case-based review. Lötscher F; Krusche M; Ruffer N; Kubacki T; Person F; Kötter I Rheumatol Int; 2019 Nov; 39(11):2005-2014. PubMed ID: 31401698 [TBL] [Abstract][Full Text] [Related]
5. Renal manifestations of recreational drugs: A narrative review of the literature. Kannan L Medicine (Baltimore); 2022 Dec; 101(50):e31888. PubMed ID: 36550840 [TBL] [Abstract][Full Text] [Related]
6. Susac-like syndrome in a chronic cocaine abuser: could levamisole play a role? Hantson P; Di Fazio V; Del Mar Ramirez Fernandez M; Samyn N; Duprez T; van Pesch V J Med Toxicol; 2015 Mar; 11(1):124-8. PubMed ID: 25142038 [TBL] [Abstract][Full Text] [Related]
9. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. Gouzoulis-Mayfrank E; Daumann J J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477 [TBL] [Abstract][Full Text] [Related]
10. The insults of illicit drug use on male fertility. Fronczak CM; Kim ED; Barqawi AB J Androl; 2012; 33(4):515-28. PubMed ID: 21799144 [TBL] [Abstract][Full Text] [Related]
11. Cardiotoxic effects of cocaine and anabolic-androgenic steroids in the athlete. Welder AA; Melchert RB J Pharmacol Toxicol Methods; 1993 Apr; 29(2):61-8. PubMed ID: 8318715 [TBL] [Abstract][Full Text] [Related]
12. Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation. Seger D Clin Toxicol (Phila); 2010 Aug; 48(7):695-708. PubMed ID: 20849328 [TBL] [Abstract][Full Text] [Related]
13. "How high do they look?": identification and treatment of common ingestions in adolescents. Woo TM; Hanley JR J Pediatr Health Care; 2013; 27(2):135-44. PubMed ID: 23414979 [TBL] [Abstract][Full Text] [Related]
15. Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances. Di Trana A; Berardinelli D; Montanari E; Berretta P; Basile G; Huestis MA; Busardò FP Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498947 [TBL] [Abstract][Full Text] [Related]
16. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Campbell GA; Rosner MH Clin J Am Soc Nephrol; 2008 Nov; 3(6):1852-60. PubMed ID: 18684895 [TBL] [Abstract][Full Text] [Related]
17. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Fantegrossi WE; Wilson CD; Berquist MD Drug Metab Rev; 2018 Feb; 50(1):65-73. PubMed ID: 29385930 [TBL] [Abstract][Full Text] [Related]
18. MDMA interactions with pharmaceuticals and drugs of abuse. Papaseit E; Pérez-Mañá C; Torrens M; Farré A; Poyatos L; Hladun O; Sanvisens A; Muga R; Farré M Expert Opin Drug Metab Toxicol; 2020 May; 16(5):357-369. PubMed ID: 32228243 [No Abstract] [Full Text] [Related]
19. Lupus anticoagulant and ANCA associated thrombotic vasculopathy due to cocaine contaminated with levamisole: a case report and review of the literature. Gulati S; Donato AA J Thromb Thrombolysis; 2012 Jul; 34(1):7-10. PubMed ID: 22437653 [TBL] [Abstract][Full Text] [Related]
20. Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated autoimmunity. Lood C; Hughes GC Rheumatology (Oxford); 2017 Apr; 56(4):638-643. PubMed ID: 27354687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]